Influence of Organic Cation Transporter 3 (SLC22A3) Genetic Polymorphisms on Antidepressant Maintenance Doses in Japanese Patients with Depression.

IF 3.1 4区心理学 Q3 NEUROSCIENCES

Neuropsychobiology Pub Date : 2025-08-26 DOI:10.1159/000548094

Kazuyuki Inoue, Kakeru Nagaoka, Natsuko Ando, Yasuhiro Hakamata, Kunihiko Itoh

{"title":"Influence of Organic Cation Transporter 3 (SLC22A3) Genetic Polymorphisms on Antidepressant Maintenance Doses in Japanese Patients with Depression.","authors":"Kazuyuki Inoue, Kakeru Nagaoka, Natsuko Ando, Yasuhiro Hakamata, Kunihiko Itoh","doi":"10.1159/000548094","DOIUrl":null,"url":null,"abstract":"Introduction: Interindividual variations in antidepressant dosages required to achieve and maintain a therapeutic response are common. To mitigate the risk of recurrence, it is recommended that patients maintain treatment at a dose that effectively alleviates their acute depressive symptoms for at least 6 months. This study investigated the relationship between the antidepressant doses used for maintenance therapy and genetic polymorphisms that affect serotonin transporter activity.Methods: Eighty-four Japanese patients with depression were enrolled in the study. For each patient, the doses of antidepressant and anxiolytic/hypnotic medications were quantified as equivalents of imipramine and diazepam, respectively, based on the most recent prescription. Patients were divided into high- and low-dose antidepressant treatment groups, using the median dose as the between-group cutoff. We examined the influence of genetic polymorphisms on inclusion in the high- and low-dose groups.Results: Multivariate logistic regression analysis revealed that the presence of the G allele in the SLC22A3 rs2292334 polymorphism was associated with an increased antidepressant maintenance dose. The odds ratio for an increased presence in the G allele of the SLC22A3 rs2292334 polymorphism was 8.867 (95% confidence interval, 1.869-42.069).Conclusion: These findings have potential use in informing future dosing strategies in depression therapy.","PeriodicalId":19239,"journal":{"name":"Neuropsychobiology","volume":" ","pages":"1-8"},"PeriodicalIF":3.1000,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuropsychobiology","FirstCategoryId":"102","ListUrlMain":"https://doi.org/10.1159/000548094","RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Interindividual variations in antidepressant dosages required to achieve and maintain a therapeutic response are common. To mitigate the risk of recurrence, it is recommended that patients maintain treatment at a dose that effectively alleviates their acute depressive symptoms for at least 6 months. This study investigated the relationship between the antidepressant doses used for maintenance therapy and genetic polymorphisms that affect serotonin transporter activity.

Methods: Eighty-four Japanese patients with depression were enrolled in the study. For each patient, the doses of antidepressant and anxiolytic/hypnotic medications were quantified as equivalents of imipramine and diazepam, respectively, based on the most recent prescription. Patients were divided into high- and low-dose antidepressant treatment groups, using the median dose as the between-group cutoff. We examined the influence of genetic polymorphisms on inclusion in the high- and low-dose groups.

Results: Multivariate logistic regression analysis revealed that the presence of the G allele in the SLC22A3 rs2292334 polymorphism was associated with an increased antidepressant maintenance dose. The odds ratio for an increased presence in the G allele of the SLC22A3 rs2292334 polymorphism was 8.867 (95% confidence interval, 1.869-42.069).

Conclusion: These findings have potential use in informing future dosing strategies in depression therapy.

查看原文本刊更多论文

有机阳离子转运体3 （SLC22A3）基因多态性对日本抑郁症患者抗抑郁药维持剂量的影响

实现和维持治疗反应所需的抗抑郁药剂量的个体间差异是常见的。为了减轻复发的风险，建议患者维持有效缓解急性抑郁症状的剂量至少6个月。本研究调查了用于维持治疗的抗抑郁药剂量与影响血清素转运体活性的遗传多态性之间的关系。方法：84例日本抑郁症患者入组研究。对于每个患者，抗抑郁药和抗焦虑/催眠药物的剂量分别根据最近的处方量化为丙咪嗪和地西泮的等量。患者被分为高剂量和低剂量抗抑郁药治疗组，使用中位数剂量作为组间截止。我们检查了遗传多态性对高剂量组和低剂量组包涵的影响。结果：多因素logistic回归分析显示，SLC22A3 rs2292334多态性中G等位基因的存在与抗抑郁药维持剂量增加有关。SLC22A3 rs2292334多态性的G等位基因存在增加的优势比为8.867（95%可信区间为1.869-42.069）。结论：这些发现对今后抑郁症治疗的给药策略有潜在的指导意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuropsychobiology 医学-精神病学

CiteScore

7.20

自引率

0.00%

发文量

审稿时长

6 months

期刊介绍： The biological approach to mental disorders continues to yield innovative findings of clinical importance, particularly if methodologies are combined. This journal collects high quality empirical studies from various experimental and clinical approaches in the fields of Biological Psychiatry, Biological Psychology and Neuropsychology. It features original, clinical and basic research in the fields of neurophysiology and functional imaging, neuropharmacology and neurochemistry, neuroendocrinology and neuroimmunology, genetics and their relationships with normal psychology and psychopathology. In addition, the reader will find studies on animal models of mental disorders and therapeutic interventions, and pharmacoelectroencephalographic studies. Regular reviews report new methodologic approaches, and selected case reports provide hints for future research. ''Neuropsychobiology'' is a complete record of strategies and methodologies employed to study the biological basis of mental functions including their interactions with psychological and social factors.